WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.
about
Current and future antiviral therapy of severe seasonal and avian influenzaStrong Public Health Recommendations from Weak Evidence? Lessons Learned in Developing Guidance on the Public Health Management of Meningococcal DiseaseEfficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza virusesOseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenzaWhat is the optimal therapy for patients with H5N1 influenza?Chronological, geographical, and seasonal trends of human cases of avian influenza A (H5N1) in Vietnam, 2003-2014: a spatial analysis.Pandemic and seasonal influenza: therapeutic challengesUpdate on influenza anti-virals.Preparing for the next influenza pandemic.Avian Influenza: a global threat needing a global solution.5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication.The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patientsInfluenza: clinical symptoms, diagnostics and therapyRecent progress and challenges in the discovery of new neuraminidase inhibitors.Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.Transparent development of the WHO rapid advice guidelinesClinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China.Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders.Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in miceNovel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutininDeveloping new antiviral agents for influenza treatment: what does the future hold?Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques.How to approach and treat viral infections in ICU patientsEffect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virusSystematic review of evidence-based guidelines on medication therapy for upper respiratory tract infection in children with AGREE instrumentImproving the use of research evidence in guideline development: 13. Applicability, transferability and adaptationAnti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.Published sequences do not support transfer of oseltamivir resistance mutations from avian to human influenza A virus strains.WHO dengue case classification 2009 and its usefulness in practice: an expert consensus in the Americas.Hypoxia Up-Regulates Galectin-3 in Mammary Tumor Progression and Metastasis.The Intersection of Care Seeking and Clinical Capacity for Patients With Highly Pathogenic Avian Influenza A (H5N1) Virus in Indonesia: Knowledge and Treatment Practices of the Public and Physicians.Methods for Developing Evidence Reviews in Short Periods of Time: A Scoping Review.Developing clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest.Predicting Disease Severity and Viral Spread of H5N1 Influenza Virus in Ferrets in the Context of Natural Exposure Routes.International guidelines: Adoption or adaptation by the Saudi Heart Association?The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panelsModeling the global transmission of antiviral-resistant influenza viruses.Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004-2005.Avian influenza A H5N1 infections in cats.Pulmonary fibrosis induced by H5N1 viral infection in mice
P2860
Q24656164-4DED562B-A7A5-42D3-B34A-643541F089F4Q26773504-9D6BC44D-2AC0-47F5-9DE5-413AA0438E04Q28473051-47C345C9-7BF9-4250-BF62-8BBFC6DE02F9Q28473860-ABC2364D-1CA9-44BB-AE87-CF19EEE56B20Q28475630-A0647005-F5CD-44ED-BE99-8333E9B8F522Q30196754-62C552DF-7969-406E-8FB4-C887A451F76FQ30228856-A9DC327A-61C9-403E-98D8-219FF58BC6FBQ30368447-D8F06558-6D2F-4665-818A-699EC37075A4Q30372312-04F53EB7-0A90-45DA-B208-3DE8B9532162Q30373347-C6C14D81-C75D-4401-A2A7-A275AD6015E1Q30389518-1313E967-EFA9-4A29-AD5B-63F5102BF3EAQ30397216-71C61096-CF3C-4A80-AD57-73403A676EE6Q30405546-A8D59FCE-A8D2-4B68-AF45-994D0F969E9FQ30426630-E8D2BBA0-33FB-4DB5-8CC3-D2CB6D9430CFQ30427798-AE855189-5D86-4FDE-8AA0-A3DF1BB901D4Q30444956-FD315368-4F72-463A-B588-6D181461BF47Q33361942-2E0F97C1-DB13-4198-ABDD-0BF81FC97117Q33687212-2EFD2C57-5698-431D-BBBC-A3402F7E67CEQ33761451-C5BBD6CA-B108-4968-BCCA-4D28CA559079Q33826751-63AAD71D-8E83-48DA-A1F0-2F6FD7FA8220Q34015113-99FDA978-3DB7-4F2E-A3A0-5AACEF2FB63AQ34058036-749FC479-38EA-4FAB-879C-9163DDC9D6EAQ34894660-73E467C4-7AA2-4271-8F70-A1052B90C552Q35076785-17153388-12FD-4C51-B886-674991E10BFFQ35105961-8556984C-4486-4B0A-AAC6-18E68F71D151Q35238209-60571385-F9E0-47D7-B1B4-D5ED5F101522Q35303234-3369DC53-1054-43DF-97AC-72418F42380DQ35607731-B6541768-B090-4481-AB29-B978EDDF80ABQ35652128-E0970C32-0397-4773-9D39-CDD0C1BA2962Q35723085-F2085F3F-6770-4A36-ABC2-051AA4AA2303Q36051337-BAC85097-EFD9-453E-BAAD-7B9B60C91D7DQ36215944-CFA5AB0C-C073-432D-81C1-777CF3ED0066Q36468650-36AE960E-B819-4F46-873B-A605439BC30BQ36523909-F19D5FE5-A8DC-4C32-B740-804A4DF1B47EQ37055599-7B38F42C-7B44-4DC5-B2D7-5FAF3830280FQ37097183-82721007-2084-4DD3-AF93-2E5BA884C358Q37105434-DA4EF6EE-DCBD-4E02-BD3C-CE195BD1FF18Q37139907-DA36CD14-EDFA-47BB-A779-5F168F25038EQ37213517-D48AA07D-B882-4D31-BC33-7E1482DF5E41Q37437349-DCE84221-D044-41E1-9B77-B8FFBF67A5C0
P2860
WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
WHO Rapid Advice Guidelines fo ...... vian influenza A (H5N1) virus.
@ast
WHO Rapid Advice Guidelines fo ...... vian influenza A (H5N1) virus.
@en
type
label
WHO Rapid Advice Guidelines fo ...... vian influenza A (H5N1) virus.
@ast
WHO Rapid Advice Guidelines fo ...... vian influenza A (H5N1) virus.
@en
prefLabel
WHO Rapid Advice Guidelines fo ...... vian influenza A (H5N1) virus.
@ast
WHO Rapid Advice Guidelines fo ...... vian influenza A (H5N1) virus.
@en
P2093
P50
P1476
WHO Rapid Advice Guidelines fo ...... vian influenza A (H5N1) virus.
@en
P2093
Alice Croisier
Azim Nagjdaliyev
Bülent Ozbay
Cathy Roth
Gail Thomson
Holger J Schünemann
Howard Zucker
Keiji Fukuda
Lauren Stockman
Meetali Kakad
P356
10.1016/S1473-3099(06)70684-3
P50
P577
2007-01-01T00:00:00Z